A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

Several new clinical trials in prostate cancer have started recruiting in recent months. Maybe one of your patients could benefit from enrolling? Metastatic castration-sensitive prostate cancer.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer. The first patient has been dosed in a phase 1/2 trial ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Mayo Clinic researchers have developed and evaluated MedEduChat, an electronic health record (EHR) that works with a large ...

Although overall quality of life was not improved with app support, use of the app had a positive effect on bowel symptoms 3 weeks after treatment. A specialized app that helps with symptom monitoring ...